Calmmax Pharma

Calmmax Pharma is a clinical-stage biopharmaceutical company headquartered in China, specializing in the development of small molecule drugs for inflammatory, respiratory, and metabolic disorders. The company focuses on targeting G protein-coupled receptors (GPCRs) and ion channels to create first-in-class or best-in-class therapies. Its lead candidate, CM001, is a GPR84 antagonist currently being evaluated for idiopathic pulmonary fibrosis and NASH. Additionally, the company is advancing CM002, a P2X3 antagonist, for the treatment of refractory chronic cough. Calmmax is supported by prominent venture capital firms and maintains research facilities in Suzhou and Shanghai.